Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Neoplasms 16Carcinoma 5Prostatic Neoplasms 2Peritoneal Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Vipoma 1Recurrence 1Neuroendocrine Tumors 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Gastrinoma 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Neoplasms 1Advanced Malignancies 1

Interventions

Paclitaxel 47Carboplatin 38liposomal doxorubicin 25Bevacizumab 23Gemcitabine 18Topotecan 15pembrolizumab 14mirvetuximab soravtansine 11rucaparib 8niraparib 7Cisplatin 71-dodecylpyridoxal 7trebananib 6Drug Therapy 6130-nm albumin-bound paclitaxel 6Nivolumab 5Cyclophosphamide 5cemiplimab 4sarilumab 3relacorilant 3pazopanib 3oregovomab 3olaparib 3Doxorubicin 3Docetaxel 3Albumin-Bound Paclitaxel 3tocilizumab 2seribantumab 2phenoxodiol 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Fallopian Tube Neoplasms × epothilone B × Clear all
NCT00262990 2020-12-17

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Novartis

Phase 3 Completed
829 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

NCT00035100 2012-04-16

EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer

Novartis

Phase 2 Completed
54 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡